Speaker
Dr
Heiko Enderling
(Moffitt Cancer Center)
Description
To date we have no understanding of why two patients with similar clinical stage and molecular profile would have different radiotherapy outcomes. Reliable biomarkers are direly needed to predict which patients will be cured, with the hope to de-escalate dose when possible or increase where necessary. It is increasingly appreciated that radiation can induce a robust antitumour immune response that provides a second wave of cell kill and tumour regression. We develop a variety of mathematical models to study the local and systemic cytotoxic and immunological consequences of radiation therapy and discuss their clinical implications.
Primary author
Dr
Heiko Enderling
(Moffitt Cancer Center)
